Drug intelligence / Profile preview

NRNT-042402

Development stage: Preclinical
Lead developer: Neurentis
Modality: Small Molecules

Overview

NRNT-042402 is a small molecule therapeutic candidate currently in the discovery phase for the treatment of depression. Developed by Neurentis in collaboration with Netellis LLC, the compound was identified using artificial intelligence and computational drug discovery methods. NRNT-042402 is designed to modulate a novel antidepressant target, the specific identity of which remains undisclosed by the developers.

Beyond the preview

Go deeper on NRNT-042402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRNT-042402.

Explore the full profile